The effects of xanthine oxidase inhibitor in patients with chronic heart failure complicated with hyperuricemia: a prospective randomized controlled clinical trial of topiroxostat vs allopurinol

The effects of xanthine oxidase inhibitor in patients with chronic heart failure complicated with hyperuricemia: a prospective randomized controlled clinical trial of topiroxostat vs allopurinol—study protocol

Published:2018-06-18 Issue:6 Volume:22 Page:1379-1386
ISSN:1342-1751
Container-title:Clinical and Experimental Nephrology
language:en
Short-container-title:Clin Exp Nephrol

Author:

Sakuma Masashi, ,Toyoda Shigeru,Arikawa Takuo,Koyabu Yota,Kato Toru,Adachi Taichi,Suwa Hideaki,Narita Jun-ichi,Anraku Koetsu,Ishimura Kimihiko,Yamauchi Fumitake,Sato Yasunori,Inoue Teruo

Funder

Sanwa Kagaku Kenkyusho, Co., Ltd

Publisher

Springer Science and Business Media LLC

Subject

Physiology (medical),Nephrology,Physiology

Link

http://link.springer.com/article/10.1007/s10157-018-1599-6/fulltext.html

Reference35 articles.

1. Feig DI, Kang DH, Johnson RJ. Uric acid and cardiovascular risk. N Engl J Med. 2008;359:1811–21.

2. Li M, Hou W, Zhang X, Hu L, Tang Z. Hyperuricemia and risk of stroke: a systematic review and meta-analysis of prospective studies. Atherosclerosis. 2014;232:265 – 70.

3. Feig DI, Mazzali M, Kang DH, Nakagawa T, Price K, Kannelis J, Johnson RJ. Serum uric acid: a risk factor and a target for treatment? J Am Soc Nephrol. 2006;17:S69-73.